ADMA ADMA Biologics Inc
Company Analysis
Latest News
ADMA Biologics Downgraded, Facing BIVIGAM Slump and Lowered 2026 Guidance
Analysts downgraded ADMA Biologics to a Hold rating on September 2, 2026. The move follows a deceleration in growth and a reduction in revenue guidance for...
BlackRock's 16.5% Stake in ADMA Biologics Signals Big-Money Confidence, but Can a Plasma Drug Company Justify the Hype?
Shares of ADMA Biologics surged 9.2% to $10.20 on August 31, bucking a softer broader market, after BlackRock disclosed ownership of roughly 38.4 million...
🟢 ADMA Biologics is trading 9.21% up in pre-market after BlackRock disclosed a 16.5% stake
ADMA Biologics is trading 9.21% up in pre-market at $10.20 after BlackRock disclosed ownership of 38,355,684 shares, representing about 16.5% of the...
BlackRock acquires 16.5% stake in ADMA Biologics for $321 million
BlackRock Inc. disclosed a new investment in ADMA Biologics on August 27, 2026. The asset manager acquired 38,355,684 shares of the biotechnology firm during...
🟢 ADMA Biologics is trading 4.7% up in pre-market amid broader risk-on sentiment
ADMA Biologics is trading 4.7% up at $10.00, most likely reflecting broader risk-on sentiment after no new company-specific announcement was identified for...
🟢 ADMA Biologics is trading 7.5% up in pre-market on positive Moderna and Merck Phase 3 results
ADMA Biologics is trading 7.5% up at $10.80, primarily on biotech-sector strength following positive Phase 3 personalized cancer-vaccine results from Moderna...
🟢 ADMA Biologics rises 4.1% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Bank of America doubles ADMA Biologics stake, joining major institutional investors
Bank of America Corp DE increased its ADMA Biologics Inc. holdings by 107.5% during the first quarter. An August 15, 2026, SEC filing confirms the bank...
🔴 ADMA Biologics is trading 4.55% down today after Berger Montague announces fiduciary-duty probe
ADMA Biologics is trading 4.55% down at $9.34 after Berger Montague announced an investigation into potential fiduciary-duty breaches by the board, including...
ADMA Biologics Board Investigated, Citing Potential Fiduciary Duty Breaches
Berger Montague PC is investigating the Board of Directors of ADMA Biologics, Inc. for potential breaches of fiduciary duty. This probe follows a series of...
ADMA Biologics Surges 10% on a Profit Beat, but Can One Star Product Carry a Company With a Shrinking Second Act?
Shares shifted sharply higher as ADMA Biologics jumped 10% to $10.19 on August 7, two days after its second-quarter earnings revealed a company being remade by...
ADMA Biologics Surges 10% on a Profit Beat, but Can One Star Product Carry a Company With a Shrinking Second Act?
Shares shifted sharply higher as ADMA Biologics jumped 10% to $10.19 on August 7, two days after its second-quarter earnings revealed a company being remade by...
🟢 ADMA Biologics is trading 10% up today after stronger profitability despite revenue miss
ADMA Biologics is trading $10.19 (+9.99%) after second-quarter earnings on August 5, 2026, showed stronger profitability despite a slight revenue miss. •...
ADMA Biologics reports a second quarter EPS beat despite a slight revenue miss, driven by 24% ASCENIV growth.
ADMA Biologics reported second quarter 2026 revenue of $124.4 million, up 2% year-over-year but slightly missing analyst estimates of $125.34 million. The...
🟢 ADMA Biologics is trading 4.2% up today ahead of Q2 earnings and biotech sector strength
ADMA Biologics is trading 4.2% up at $9.29 as traders position ahead of its second-quarter 2026 earnings release scheduled for August 05, 2026. • The stock is...
ADMA Biologics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Analysts expect ADMA Biologics to report Q2 2026 revenue of $125.34 million and EPS of $0.16, as the stock trades near $8.46 against a median analyst price...
🟢 ADMA Biologics is trading 4.1% up today despite no clear company-specific news catalyst
ADMA Biologics is trading at $9.02 (4.1% up) in after-hours trading despite a lack of fresh, company-specific headlines such as earnings, FDA decisions, or...
🔴 ADMA Biologics is trading 4.4% down today with no clear catalyst identified
ADMA Biologics is trading at $8.40 (4.4% down) in after-hours trading with no clear catalyst identified for the move. • The decline follows a recent multi-day...
ADMA Biologics faces fraud lawsuit, following alleged channel stuffing and stock crash
Multiple law firms filed a securities fraud class-action lawsuit against ADMA Biologics, Inc. The complaint alleges the company issued misleading statements...
ADMA Biologics hit with fraud lawsuit, alleging revenue inflation and hidden deals
Multiple law firms filed a securities fraud class-action lawsuit against ADMA Biologics, Inc. and its executives. The complaint alleges the company made false...